

June 14, 2021

Office of Life Sciences  
Division of Corporation Finance  
Securities and Exchange Commission  
100 F Street, N.E.  
Washington, D.C. 20549  
Attention: Jane Park

**Re: C4 Therapeutics, Inc.  
Acceleration Request for Registration Statement on Form S-1  
File No. 333-257067**

Dear Ms. Park,

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “**Act**”), C4 Therapeutics, Inc. (the “**Company**”) hereby requests that the effective date of the above-referenced registration statement (the “**Registration Statement**”) be accelerated to June 16, 2021, at 4:01 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.

Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling Shoab Ghias at (510) 759-1494. We also respectfully request that a copy of the written order from the Securities and Exchange Commission verifying the effective time and date of the Registration Statement be sent to our counsel, Goodwin Procter LLP, Attention: Shoab Ghias, by facsimile to (415) 677-9041.

If you have any questions regarding this request, please contact Shoab Ghias of Goodwin Procter LLP at (510) 759-1494.

Sincerely,

C4 THERAPEUTICS, INC.

/s/ Andrew Hirsch

---

Andrew Hirsch  
Chief Executive Officer

cc: William McKee, *C4 Therapeutics, Inc.*  
Shagha Russell, *C4 Therapeutics, Inc.*  
Lawrence S. Wittenberg, *Goodwin Procter LLP*  
Edwin O'Connor, *Goodwin Procter LLP*  
Shoab Ghias, *Goodwin Procter LLP*